Reproductive BioMedicine Online
Volume 19, Issue 4 , Pages 508-513 , October 2009

Dehydroepiandrosterone supplementation improves ovarian response and cycle outcome in poor responders

  • M Sönmezer

      Affiliations

    • Ankara University School of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey
    • Ankara University Centre for Research on Human Reproduction, Ankara, Turkey
    • Corresponding Author InformationCorrespondence:
    • ,
  • B Özmen

      Affiliations

    • Ankara University School of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey
    • Ankara University Centre for Research on Human Reproduction, Ankara, Turkey
    • ,
  • AP Çil

      Affiliations

    • Kirikkale University School of Medicine, Department of Obstetrics and Gynecology, Kirikkale, Ankara, Turkey
    • ,
  • S Özkavukçu

      Affiliations

    • Ankara University School of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey
    • Ankara University Centre for Research on Human Reproduction, Ankara, Turkey
    • ,
  • T Taşçı

      Affiliations

    • Ankara University Centre for Research on Human Reproduction, Ankara, Turkey
    • ,
  • H Olmuş

      Affiliations

    • Gazi University, Faculty of Science and Art, Department of Statistics, Ankara, Turkey
    • ,
  • CS Atabekoğlu

      Affiliations

    • Ankara University School of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey
    • Ankara University Centre for Research on Human Reproduction, Ankara, Turkey

Received 11 January 2009 ,Revised 3 February 2009 ,Accepted 19 June 2009.

References 

  1. Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Human Reproduction. 2006;21:2845–2849
  2. Barad D, Gleicher N. Increased oocyte production after treatment with dehydroepiandrosterone. Fertility and Sterility. 2005;84:756
  3. Barad D, Brill H, Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian reserve. Journal of Assisted Reproduction and Genetics. 2007;24:629–634
  4. Casson PR, Lindsay MS, Pisarska MD, et al. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Human Reproduction. 2000;15:2129–2132
  5. Casson PR, Carson SA, Buster JE, et al. Replacement dehydroepiandrosterone in elderly: rationale and prospects for the future. Endocrinologist. 1998;8:187–194
  6. Casson PR, Santoro N, Elkind-Hirsch K, et al. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six month trial. Fertility and Sterility. 1998;70:107–110
  7. de Leo V, Lanzetta D, D’Antona D, et al. Hormonal effects of flutamide in young women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism. 1998;83:99–102
  8. Gleicher N, Barad D. Ovarian age-based’ stimulation of young women with diminished ovarian reserve results in excellent pregnancy rates with in vitro fertilization. Fertility and Sterility. 2006;86:1621–1625
  9. Gleicher N, Ryan E, Weghofer A, et al. Dehydroepiandrosterone (DHEA) reduces miscarriage rates in women wıth diminished ovarian reserve: a multicenter study. Fertility and Sterility. 2008;90(Suppl. 1):S258
  10. Gleicher N, Weghofer A, Barad D. Increased euploid embryos after supplementation with dehydroepiandrosterone (DHEA) in women with premature ovarian aging. Fertility and Sterility. 2007;88(Suppl. 1):S232
  11. Haning R, Hackett R, Flood C, et al. Plasma dehydroepiandrosterone sulfate serves as a prehormone for 48% of follicular fluid testosterone during treatment with menotropins. Journal of Clinical Endocrinology and Metabolism. 1993;76:1301–1307
  12. Harlow CR, Hillier SG, Hodges JK. Androgen modulation of follicle-stimulating hormone induced granulosa cell steroidogenesis in the primate ovary. Endocrinology. 1986;119:1403–1405
  13. Hillier SG, De Zwart FA. Evidence that granulosa cell aromatase induction/activation by follicle-stimulating hormone is an androgen receptor-regulated process in-vitro. Endocrinology. 1981;109:1303–1305
  14. Hugues JN, Durnerin IC. Impact of androgens on fertility – physiological, clinical and therapeutic aspects. Reproductive BioMedicine Online. 2005;11:570–580
  15. Mamas L, Mamas E. Premature ovarian failure and dehydroepiandrosterone. Fertility and Sterility. 2009;91:644–646
  16. Orentreich N, Brind JL, Rizer RL, et al. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. Journal of Clinical Endocrinology and Metabolism. 1984;59:551–555
  17. Ryan E, Claessens EA, Blanco Mejia S. The sex ratio of offspring born to women, using dehydroepiandrosterone (DHEA) to improve ovarian response. Fertility and Sterility. 2008;88(Suppl. 1):S116
  18. Siristatidis CS, Hamilton MP. What should be the maximum FSH dose in IVF/ICSI in poor responders?. Journal of Obstetrics and Gynaecology. 2007;27:401–405
  19. Vendola K, Zhou J, Wang J, et al. Androgens promote oocyte insulin-like growth factor I expression and initiation of follicle development in the primate ovary. Biology of Reproduction. 1999;61:353–357
  20. Vendola K, Zhou J, Adesanya OO, et al. Androgens stimulate early stages of follicular growth in the primate ovary. Journal of Clinical Investigation. 1998;101:2622–2629
  21. Wachs DS, Coffler MS, Malcom PJ, et al. Increased androgen response to follicle-stimulating hormone administration in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism. 2008;93:1827–1833
  22. Weil SJ, Vendola K, Zhou J, et al. Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations. Journal of Clinical Endocrinology and Metabolism. 1998;83:2479–2485

 Murat Sönmezer completed his postdoctoral research fellowship at the Center of Reproductive Medicine and Infertility of the Cornell University in 2003. He is especially interested in cryopreservation of ovarian tissue, fertility preservation technologies in cancer patients and management of patients with diminished or poor ovarian reserve.Dr Murat Sönmezer

PII: S1472-6483(09)00021-2

doi: 10.1016/j.rbmo.2009.06.006

Reproductive BioMedicine Online
Volume 19, Issue 4 , Pages 508-513 , October 2009

Article Tools